Yes, mycelium from Psilocybe species does contain psilocybin, but in dramatically lower concentrations than the mushrooms (fruiting bodies) it eventually produces. In Psilocybe cubensis, fruiting bodies average about 9.9 mg/g of psilocybin, while mycelium contains roughly 0.04 mg/g. That makes the mushroom itself about 240 times more concentrated than its underlying fungal network.
How Much Psilocybin Is in Mycelium
A 2023 study published in Frontiers in Fungal Biology measured psilocybin across three life stages of Psilocybe: pure mycelium, grain colonized by mycelium, and mature fruiting bodies. The results were stark. Fruiting bodies averaged 9.913 mg/g of psilocybin by dry weight. Pure mycelium came in at 0.041 mg/g, and grain mycelium (the kind you’d find in a colonized jar) was nearly identical at 0.047 mg/g.
To put that in practical terms, you would need roughly 240 grams of dried mycelium to get the same amount of psilocybin found in a single gram of dried mushroom. The psilocybin is technically present, but at trace levels.
Interestingly, not every compound follows the same pattern. Psilocin, norpsilocin, and aeruginascin showed no significant difference between mycelium and fruiting bodies. The gap is specific to psilocybin and a few related compounds like baeocystin and norbaeocystin, which all accumulate heavily during the fruiting stage.
Why Fruiting Bodies Concentrate Psilocybin
Mycelium is the vegetative stage of the fungus. It functions like a root system, spreading through soil or substrate to absorb nutrients. The mushroom itself is a reproductive structure, built to produce and release spores. During fruiting, the fungus shifts its chemical machinery into a different gear, rapidly synthesizing and stockpiling psilocybin and related alkaloids in the cap and stem tissue.
The biosynthetic pathway that creates psilocybin starts with tryptophan, an amino acid. That same study found tryptophan levels were significantly higher in fruiting bodies than in mycelium, suggesting the fungus actively channels this building block toward alkaloid production as it fruits. The mycelium can run this pathway too, just at a much lower rate. Think of it as the difference between a factory running at idle versus full production.
Mycelium on Grain vs. Pure Mycelium
Many people encounter mycelium not as a pure culture but growing on grain, rice, or another substrate. The psilocybin content of grain mycelium (0.047 mg/g) was virtually identical to pure mycelium (0.041 mg/g) in laboratory testing. The substrate itself doesn’t meaningfully boost alkaloid production. This matters because some commercial “mycelium” products are largely grain with a thin layer of fungal growth. The grain dilutes the already-low alkaloid concentration even further.
Other Compounds in Mycelium
While psilocybin levels are low, mycelium isn’t chemically empty. The same analysis found that mycelium contains a range of other fungal metabolites, though fruiting bodies still had higher levels of most. Compounds like ergothioneine (a potent antioxidant), choline, glutamate, and pantothenic acid were all present across life stages. Some of these have their own biological activity, which is one reason researchers remain interested in mycelium even when psilocybin isn’t the goal.
The relatively even distribution of psilocin across life stages is also notable. Psilocin is the compound that actually crosses the blood-brain barrier and produces psychoactive effects. Psilocybin itself is a “prodrug” that your body converts into psilocin after ingestion. The fact that psilocin levels don’t differ significantly between mycelium and fruiting bodies suggests the two life stages handle this particular molecule differently than they handle psilocybin.
Growing Mycelium for Psilocybin Production
Despite the low concentrations, mycelium-based production is attracting serious pharmaceutical interest. The reason is consistency. Mycelium grows more uniformly than mushrooms, which vary widely in potency from one flush to the next, or even from one cap to the stem of the same mushroom. A bioreactor filled with liquid culture can, in theory, produce mycelium with more predictable chemical profiles batch after batch.
Early research on submerged fermentation of Psilocybe cubensis actually predates most studies on fruiting bodies. Scientists demonstrated decades ago that adjusting temperature, nutrients, and oxygen levels during liquid cultivation could shift the yield of psilocybin in mycelial biomass. The challenge has always been getting those yields high enough to compete with the natural concentration in mushrooms.
For pharmaceutical applications, the appeal goes beyond chemistry. Mycelium grown in controlled fermentation tanks is easier to standardize, easier to keep free of contaminants, and more compatible with the kind of regulatory documentation agencies require for drug approval. Several research groups are now working to optimize these systems, though the field is still in its early stages for Psilocybe species specifically. The techniques are well established for non-psychoactive fungi but haven’t yet been fully adapted.
The Bottom Line on Potency
Mycelium contains psilocybin. It is not psilocybin-free. But the concentration is so low, roughly 0.4% of what you’d find in a dried mushroom, that it’s essentially a trace amount. If your question is whether mycelium-colonized grain “counts” as containing a controlled substance, the answer is yes from a chemistry standpoint, and potentially yes from a legal one depending on jurisdiction. If your question is whether mycelium delivers meaningful amounts of psilocybin compared to fruiting bodies, the answer is no, not without industrial-scale extraction or optimization that doesn’t yet exist at a practical level.